What Makes Becton Dickinson (BDX) a Good Long-Term Investment?

2 days ago 4

Soumya Eswaran

Wed, November 19, 2025 astatine 7:27 AM CST 4 min read

Cullen Capital Management, LLC, operating nether the name Schafer Cullen Capital Management, Inc. (SCCM), has released its “SCCM Value Equity Strategy” third-quarter capitalist letter. A transcript of the missive tin beryllium downloaded here. The US equity marketplace continued the rally successful the 3rd quarter, with the S&P 500 returning 8.1% and the Russell 1000 Value surging 5.3%. The worth equity strategy returned 6.9% (gross of fees) and 6.8% (net of fees) successful the quarter, portion the Russell 1000 Value and S&P 500 returned 5.3% and 8.1%, respectively, during the aforesaid period. The strategy returned 13.0% (gross), YTD, compared to the Russell 1000 Value’s +11.7% instrumentality and the S&P 500’s +14.8% return. In addition, you tin cheque the fund’s apical 5 holdings to find its champion picks for 2025.

In its third-quarter 2025 capitalist letter, SCCM Value Equity Strategy highlighted stocks specified arsenic Becton, Dickinson and Company (NYSE:BDX). Becton, Dickinson and Company (NYSE:BDX) is simply a healthcare institution that develops and manufactures aesculapian supplies, devices, laboratory equipment, and diagnostic products. The one-month instrumentality of Becton, Dickinson and Company (NYSE:BDX) was 2.24%, and its shares mislaid 13.52% of their worth implicit the past 52 weeks. On November 18, 2025, Becton, Dickinson and Company (NYSE:BDX) banal closed astatine $192.33 per share, with a marketplace capitalization of $55.127 billion.

SCCM Value Equity Strategy stated the pursuing regarding Becton, Dickinson and Company (NYSE:BDX) successful its 3rd 4th 2025 capitalist letter:

"Becton, Dickinson and Company (NYSE:BDX) was purchased successful the Value strategy. BDX is simply a planetary aesculapian exertion institution engaged successful the development, manufacture and merchantability of a wide scope of aesculapian supplies, devices, laboratory instrumentality and diagnostic products utilized by hospitals, aesculapian offices, physicians, objective laboratories, and the pharmaceutical industry. Its BD Medical (50% of 2024 sales) conception focuses connected devices for medicine delivery, including syringes, needles, infusion pumps, pre-filled syringes and related pharmaceutical services. BD is the world’s largest shaper of syringes, with implicit 80% marketplace stock successful US infirmary syringes. Its BD Life Sciences (26%) conception provides products and services for illness detection and research, with offerings including diagnostic systems, travel cytometry instruments, and reagents utilized successful laboratories for illness recognition and monitoring. Its BD Interventional (24%) conception offers surgical and interventional devices, specified arsenic catheters and vascular entree tools.